Drug intelligence / Profile preview

umbilical cord blood CD34+ cell-derived CD161- innate lymphoid cells type 1

Development stage: Preclinical
Modality: Cell Therapies
Administration: Intravenous

Overview

Umbilical cord blood CD34+ cell-derived CD161- innate lymphoid cells type 1 is an experimental adoptive cell therapy being investigated for the treatment of acute myeloid leukemia (AML). This therapy involves the generation of a specific subset of type 1 innate lymphoid cells (ILC1s), characterized as Lin-CD127+CD161-CRTH2-CD117-, from healthy donor umbilical cord blood CD34+ hematopoietic stem cells. These ILC1s exert anti-leukemic effects by secreting Tumor Necrosis Factor alpha (TNFα) and Interferon gamma (IFNγ). TNFα inhibits the transition of leukemia stem cells (LSCs) into immunosuppressive macrophage-like cells, while IFNγ suppresses the differentiation of leukemic blasts. This approach aims to overcome the functional impairment of endogenous ILC1s observed in AML patients, thereby limiting leukemogenesis and potentially prolonging disease-free survival.

Other names: CD161- ILC1sCD-161- ILC1sCD 161- ILC1sUCB-derived CD161- ILC1sumbilical cord blood-derived ILC1s

Beyond the preview

Go deeper on umbilical cord blood CD34+ cell-derived CD161- innate lymphoid cells type 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on umbilical cord blood CD34+ cell-derived CD161- innate lymphoid cells type 1.

Explore the full profile